Shamburg News · 8-K filed Nov 9, 2026, 4:02 PM EST

Aldeyra Therapeutics Requests FDA Review Transfer for ADX-2191 IND and Withdraws PVRL SPA

ALDX · Aldeyra Therapeutics, Inc.

  • Other event
  • Material agreement
  • Other
  • Materiality: high

On November 9, 2026, Aldeyra Therapeutics announced it requested that the FDA Division of Ophthalmology submit a review jurisdiction request recommending transfer of the ADX-2191 IND for primary vitreoretinal lymphoma to the Division of Hematologic Malignancies 2. In connection with the request, Aldeyra notified the FDA it had withdrawn the Special Protocol Assessment protocol for ADX-2191 in PVRL. The company does not expect to initiate the planned clinical trial while the request is pending, and the filing adds a risk factor noting the regulatory path is uncertain and may be significantly delayed.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001193125-26-453537.

Written from the filing by Shamburg Markets. Figures are as reported by the company.